
    
      The central hypothesis is that 6 months of administration of high dose omega-3 fatty acid
      esters [eicosapentaenoic acid (EPA) 1860 mg, and docosahexaenoic acid (DHA) 1500 mg] daily in
      the form of a standard prescription strength dose of Lovazaâ„¢ (two 1 gram capsules twice
      daily) will have a favorable side effect profile and potential efficacy as demonstrated by
      favorable modulation of one or more blood and breast tissue risk biomarkers for breast cancer
      in premenopausal women.
    
  